Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the ELSS median (51 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 29 Dec 2015 – 20 Aug 2026. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one. Nifty 500 history starts 25 Jul 2016, so that benchmark is not plotted over this window — pick a shorter range to see it.
View as table
| Date | Mirae Asset ELSS Tax Saver Fund |
|---|---|
| 29 Dec 2015 | ₹100.00 |
| 17 Nov 2016 | ₹115.07 |
| 07 Oct 2017 | ₹155.42 |
| 27 Aug 2018 | ₹176.10 |
| 17 Jul 2019 | ₹178.92 |
| 05 Jun 2020 | ₹161.35 |
| 25 Apr 2021 | ₹248.98 |
| 14 Mar 2022 | ₹294.79 |
| 01 Feb 2023 | ₹304.77 |
| 22 Dec 2023 | ₹389.14 |
| 10 Nov 2024 | ₹469.58 |
| 30 Sep 2025 | ₹482.93 |
| 20 Aug 2026 | ₹507.03 |
| Metric | Mirae Asset · Regular NAV ₹50.85 Very High risk ★★★★☆ | Category median ELSS · 51 funds |
|---|---|---|
| +3.83% | +2.06% | |
| +13.35% | +13.00% | |
| +11.74% | +12.22% | |
| +15.79% | +12.69% | |
| +16.48% | +13.09% | |
| +11.67% | — | |
| +17.13% | +14.73% | |
| +18.20% | +15.15% | |
| +17.08% | +14.10% | |
| Risk | ||
| 13.97% | 14.18% | |
| 0.49 | 0.47 | |
| 0.67 | 0.63 | |
| -37.97% | -37.97% | |
| Nifty 500 | — | |
| +1.11% | +0.84% | |
| 1.00 | 0.97 | |
| 101.0% | 100.1% | |
| 94.5% | 95.6% | |
| 1.98% | 1.93% | |
| ₹25,328Cr | ₹857.48Cr | |
| None | — | |
| 3 years | — | |
| ₹500 | — | |
| ₹500 | — | |
| 69% | 33% | |
| Neelesh Surana · 10.8y | — | |
| 29 Dec 2015 | — | |
| 66 | — | |
| 40.5% | — | |
| 0.9% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.